Insmed (NASDAQ:INSM) Shares Gap Up – What’s Next?

Insmed, Inc. (NASDAQ:INSM) gapped up before the market opened on Monday . The stock had previously closed at $136.00, but opened at $147.12. Insmed shares last traded at $145.72, with a volume of 849,820 shares traded.

More Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Positive Phase 3b ENCORE topline results for ARIKAYCE support label expansion and larger market opportunity; Insmed plans to file a supplemental NDA with the FDA and submit data to Japan’s PMDA in H2 2026. This is the primary fundamental catalyst behind recent upside for the shares. PR Newswire: ENCORE topline
• Positive Sentiment: Multiple brokerages raised price targets (Leerink to $215, Bank of America to $213, Stifel to $208), signaling analyst confidence and implying ~50%+ upside from current levels — providing buy-side support. Benzinga: price target updates
• Positive Sentiment: Analyst commentary and coverage (including a Seeking Alpha “Strong Buy” piece) frame the ENCORE data as a material commercial opportunity — potential first-line MAC label expansion, conversion of accelerated approval and additional international upside. Seeking Alpha: Strong Buy
• Neutral Sentiment: Widespread media coverage (Zacks, MarketWatch, CNBC, Stat/others) amplified the clinical news and drove intraday momentum; these reports support short-term volatility but are secondary to the underlying trial outcome. Zacks: Arikayce hits goal
• Neutral Sentiment: Short-interest reports in the feed show large increases but the published figures read as 0/NaN and inconsistent across sources — the data appears unreliable and should not be treated as confirmed short‑squeeze signal.
• Negative Sentiment: Insider selling: the CEO sold roughly $1.54M of stock, which can raise governance/near‑term sentiment concerns even when filings show routine sales. AmericanBankingNews: Insider sale
• Negative Sentiment: Wells Fargo trimmed its price target to $175 (still “overweight”) — a relative cut vs. other firms that may have contributed to profit‑taking and intraday weakness.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. TD Cowen set a $241.00 price objective on Insmed in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Wolfe Research set a $167.00 price target on shares of Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $230.00 price target on shares of Insmed in a report on Monday, February 23rd. Finally, Roth Mkm raised shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $209.38.

Insmed Stock Down 3.4%

The firm’s 50-day simple moving average is $150.99 and its 200 day simple moving average is $166.23. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The stock has a market capitalization of $29.99 billion, a P/E ratio of -21.71 and a beta of 1.13.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The company had revenue of $263.84 million during the quarter, compared to the consensus estimate of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. Insmed’s revenue was up 152.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.32) EPS. As a group, research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In other news, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares in the company, valued at $51,864,579. This represents a 5.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the sale, the insider directly owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 189,651 shares of company stock valued at $31,533,654 over the last three months. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CoreCap Advisors LLC bought a new position in shares of Insmed in the fourth quarter valued at about $27,000. Reflection Asset Management bought a new stake in shares of Insmed during the 4th quarter worth about $30,000. GraniteShares Advisors LLC bought a new stake in shares of Insmed during the 4th quarter worth about $30,000. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 53 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Insmed in the 4th quarter valued at about $32,000.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.